BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27880934)

  • 1. Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients.
    Fu T; Liu Y; Li K; Wan W; Pappou EP; Iacobuzio-Donahue CA; Kerner Z; Baylin SB; Wolfgang CL; Ahuja N
    Oncotarget; 2016 Dec; 7(52):86480-86489. PubMed ID: 27880934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and prognosis value of the CIMP status combined with MLH1 or p16
    Saadallah-Kallel A; Abdelmaksoud-Dammak R; Triki M; Charfi S; Khabir A; Sallemi-Boudawara T; Mokdad-Gargouri R
    Med Oncol; 2017 Aug; 34(8):147. PubMed ID: 28730335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.
    Fu T; Pappou EP; Guzzetta AA; Jeschke J; Kwak R; Dave P; Hooker CM; Morgan R; Baylin SB; Iacobuzio-Donahue CA; Wolfgang CL; Ahuja N
    Clin Cancer Res; 2012 Sep; 18(17):4743-52. PubMed ID: 22825585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
    Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
    Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
    Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subsets of microsatellite-unstable colorectal cancers exhibit discordance between the CpG island methylator phenotype and MLH1 methylation status.
    Kim JH; Rhee YY; Bae JM; Kwon HJ; Cho NY; Kim MJ; Kang GH
    Mod Pathol; 2013 Jul; 26(7):1013-22. PubMed ID: 23370766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
    Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
    Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.
    Kim CH; Huh JW; Kim HR; Kim YJ
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1469-1474. PubMed ID: 28087988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
    Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
    Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of MLH1 Methylation and CpG Island Methylator Phenotype as Prognostic Markers in Patients with Gastric Cancer.
    Shigeyasu K; Nagasaka T; Mori Y; Yokomichi N; Kawai T; Fuji T; Kimura K; Umeda Y; Kagawa S; Goel A; Fujiwara T
    PLoS One; 2015; 10(6):e0130409. PubMed ID: 26121593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer.
    Chen KH; Lin LI; Tseng LH; Lin YL; Liau JY; Tsai JH; Liang JT; Lin BR; Cheng AL; Yeh KH
    Oncology; 2019; 96(3):156-163. PubMed ID: 30540994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci.
    Kawasaki T; Ohnishi M; Nosho K; Suemoto Y; Kirkner GJ; Meyerhardt JA; Fuchs CS; Ogino S
    Mod Pathol; 2008 Mar; 21(3):245-55. PubMed ID: 18204436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dynamic DNA methylation landscape of the
    Savio AJ; Mrkonjic M; Lemire M; Gallinger S; Knight JA; Bapat B
    Clin Epigenetics; 2017; 9():26. PubMed ID: 28293327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.
    Juo YY; Johnston FM; Zhang DY; Juo HH; Wang H; Pappou EP; Yu T; Easwaran H; Baylin S; van Engeland M; Ahuja N
    Ann Oncol; 2014 Dec; 25(12):2314-2327. PubMed ID: 24718889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
    Ogino S; Kawasaki T; Kirkner GJ; Kraft P; Loda M; Fuchs CS
    J Mol Diagn; 2007 Jul; 9(3):305-14. PubMed ID: 17591929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
    Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
    Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer.
    Kawasaki T; Ohnishi M; Suemoto Y; Kirkner GJ; Liu Z; Yamamoto H; Loda M; Fuchs CS; Ogino S
    Mod Pathol; 2008 Feb; 21(2):150-8. PubMed ID: 18084250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.
    Cha Y; Kim KJ; Han SW; Rhee YY; Bae JM; Wen X; Cho NY; Lee DW; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Kang GH; Kim TY
    Br J Cancer; 2016 Jul; 115(2):164-71. PubMed ID: 27310704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.